Keen Vision Acquisition Corporation is a SPAC — a publicly listed shell company with no operations. Keen Vision raised ~$149.5M in its July 2023 IPO and deposited ~$151.4M into a trust account, which earns interest while the company searches for an acquisition target. Keen Vision has been focused on biotech, consumer goods, or agriculture, with a preference for companies with global market potential and target enterprise values under $1B. As of the filing, Keen Vision has signed a binding LOI to merge with Novoheart Group Limited, a pre-clinical human disease modeling and drug discovery company and subsidiary of Medera, at an enterprise value of $100M, with a formal merger agreement targeted for signing in April 2026. Keen Vision itself generates no revenue. Its business model centers on the sponsor — KVC Sponsor LLC — receiving founder shares and private units at nominal cost, which become valuable only if a business combination closes. If no deal closes, the trust is liquidated, public shareholders are returned at least ~$10.125 per share, and the sponsor loses its investment. To extend the deal deadline, the sponsor has deposited additional funds via promissory notes totaling ~$2.8M. The business combination deadline has been extended multiple times and currently runs through at least April 27, 2026. Keen Vision has no full-time employees, and neither the CEO nor CFO is required to work for the company on a full-time basis.